Tumor microenvironments self-activated nanoscale metal-organic frameworks for ferroptosis based cancer chemodynamic/photothermal/chemo therapy

Yu Liang\textsuperscript{a,b,\textdagger}, Li Zhang\textsuperscript{a,\textdagger}, Chao Peng\textsuperscript{a,b,\textdagger}, Shiyu Zhang\textsuperscript{a}, Siwen Chen\textsuperscript{b}, Xin Qian\textsuperscript{b}, Wanxian Luo\textsuperscript{a}, Qing Dan\textsuperscript{a}, Yongyan Ren\textsuperscript{d}, Yingjia Li\textsuperscript{a,\textasteriskcentered}, Bingxia Zhao\textsuperscript{b,\textasteriskcentered}

\textsuperscript{a}Department of Medicine Ultrasonics, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
\textsuperscript{b}Guangzhou Key Laboratory of Tumor Immunology Research, Cancer Research Institute, School of Basic Medical Sciences, Southern Medical University, Guangzhou 510515, China
\textsuperscript{c}Department of Cerebrovascular Diseases, Zhuhai People's Hospital (Zhuhai Hospital Affiliated with Jinan University), Zhuhai 519099, China
\textsuperscript{d}Central Laboratory, Southern Medical University, Guangzhou 510515, China

Received 20 December 2020; received in revised form 8 January 2021; accepted 15 January 2021

Abstract  Ferroptosis, as a newly discovered cell death form, has become an attractive target for precision cancer therapy. Several ferroptosis therapy strategies based on nanotechnology have been reported by either increasing intracellular iron levels or by inhibition of glutathione (GSH)-dependent lipid hydroperoxide glutathione peroxidase 4 (GPX4). However, the strategy by simultaneous iron delivery and GPX4 inhibition has rarely been reported. Herein, novel tumor microenvironments (TME)-activated metal-organic frameworks involving Fe & Cu ions bridged by disulfide bonds with PEGylation (FCSP MOFs) were developed, which would be degraded specifically under the redox TME, simultaneously achieving GSH-depletion induced GPX4 inactivation and releasing Fe ions to produce ROS via Fenton reaction, therefore causing ferroptosis. More ROS could be generated by the acceleration of Fenton reaction due to the released Cu ions and the intrinsic photothermal capability of FCSP MOFs. The over-expressed GSH and H\textsubscript{2}O\textsubscript{2} in TME could ensure the specific TME self-activated therapy. Better tumor therapeutic efficiency could be achieved by doxorubicin (DOX) loading since it can not only cause

*Corresponding authors.

E-mail addresses: lyjia@smu.edu.cn (Yingjia Li), bingxia@gmail.com, bingxia@foxmail.com (Bingxia Zhao).

\textdagger}These authors made equal contributions to this work.

Peer review under the responsibility of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.

https://doi.org/10.1016/j.apsb.2021.01.016

2211-3835 © 2021 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
apoptosis, but also indirectly produce H$_2$O$_2$ to amplify Fenton reaction. Remarkable anti-tumor effect of obtained FCSP@DOX MOFs was verified via both in vitro and in vivo assays.

© 2021 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Ferroptosis, an iron-dependent non-apoptotic form of regulated cell death, which was termed in 2012 by Dixon et al. Numerous researches have been carried out to uncover the mechanisms of ferroptosis over these years. Some regulation mechanisms and signal pathways have already been identified, such as cystine/glutamate antiporter system xc$^-$ for cystine import, the Acyl-CoA synthetase long-chain family member 4 (ACSL4) enzyme about lipid metabolism, malonate pathway about the production of coenzyme Q10 (CoQ10) for ferroptosis inhibition, nicotinamide adenine dinucleotide phosphate (NADPH) and selenium abundance for ferroptosis resistance. The defining feature of ferroptosis requires for iron and accumulation of reactive oxygen species (ROS). It is reported that the metabolism of iron impacts ferroptosis sensitivity and the iron is required for the lipid peroxides accumulation to cause the ferroptosis execution. Moreover, the glutathione (GSH)-dependent lipid hydroperoxidase glutathione peroxidase 4 (GPX4) exerts a pivotal function on ferroptosis resistance. The definition of feature of ferroptosis was also reported to have the ability of consuming intracellular GSH, thereby obtaining a better therapeutic effect. A tumor-targeted manganese silicate nanobubbles (ASMNs) was successfully synthesized to indirectly induce ferroptosis by high efficient GSH depletion.

In 2018, Dixon et al. concluded the major strategies to induce cell ferroptosis as by increasing intracellular iron levels or direct/indirect inhibition of the GPX4 activity. Emerging studies based on nanotechnology were reported following these strategies utilizing the unique physicochemical properties of nanomaterials. Several nanoplatforms have been developed by iron delivery, inducing iron-based Fenton reaction to generate hydroxyl radical (·OH, one of the most toxic ROS), such as cerium oxide nanoparticles (CeO$_2$ NPs), iron nanometric glasses, iron-containing upconversion nanoparticles. The therapeutic strategy by iron delivery to induce Fenton reaction was also known as chemodynamic therapy. Moreover, some nanoplatforms based on Fe ions containing metal-organic frameworks (MOFs) were also designed utilizing the flexibility and better tumor microenvironments responsiveness of MOFs compared with stable inorganic nanomaterials. For example, a metal–organic network combined with tannic-acid and ferric ions were encapsulated with p53 plasmid (MON-p53), which performed significantly enhance ferroptosis effect through synergetic ferroptosis/p53 gene therapy. In addition, a reduced iron MOF conjugated with folic acid (rMOF-FA) had achieved folate-mediated tumor targeting and acidic tumor microenvironments induced Fe release for tumor specific ferroptosis. However, researches on MOFs for ferroptosis therapy, especially redox-sensitive MOFs, is still insufficient and their promising future in ferroptosis remains worth exploring further. As it has been reported, the catalytic efficiency of Fe-dependent ·OH generation could be further improved by auxiliary treatments, such as light and heat. Copper (Cu)-based materials with good photothermal conversion efficiency could result in more ·OH generation through accelerating Fe-based Fenton reaction by laser-induced heat. Interestingly, some recent reports revealed that copper (Cu) ions could also induce the production of ·OH by Fenton-like reaction. In other words, the fabrication of Fe & Cu dual ions-based MOFs may achieve better ferroptosis efficiency, which has rarely been reported.

Despite of the development of nanoplatforms to induce ferroptosis through iron-based Fenton reaction nanomaterials, some attempts were also carried to induce ferroptosis by suppressing or consuming the overexpressed GSH (up to 10 mmol/L in cancer cell) to inactivate GPX4 indirectly. For instance, an engineered cysteine enzyme was employed to block intratumoral GSH synthesis through reducing l-cysteine, a precursor for the biosynthesis of GSH, thereby obtaining a better therapeutic effect. A tumor-targeted manganese silicate nanobubbles (ASMNs) was successfully synthesized to indirectly induce ferroptosis by high efficient GSH depletion. Some attempts based on MnO$_2$ nanosystems were also reported to have the ability of consuming intracellular antioxidant GSH for enhancing ROS induced oncotherapy.

On the other hand, the depletion of GSH would not only induce ferroptosis, but also enhance the ROS-related therapy, such as radio-, chemo-, and photodynamic therapies (PDT), as GSH was well-known as intracellular antioxidant which would consume the cytotoxic ROS to maintain the homeostasis. Some attempts developed a Ce6-loaded glutathione responsive MOF which could cause the intracellular GSH depletion via the disulfide–thiol exchange reaction, indirectly causing the GPX4 inactivation-induced ferroptosis, therefore making contributions to the anti-tumor effect of PDT. The therapeutic effect, however, still mainly depended on the PDT effect of Ce6. It would be still worthy to develop novel nanoplatforms for ferroptosis therapy by GSH depletion.

Though successful attempts have been reported by either iron delivery or GPX4 inhibition, only limited work utilized the two strategies simultaneously in one platform for cancer ferroptosis therapy. Liu et al. established core-corona SRF@FeIIIIA (SFT) nanoengineering for simultaneous ferrous-supply-regeneration and sorafenib (a GPX4 inhibitor) to induce ferroptosis, thereby
achieving complete tumor elimination with the assistance of imaging-guided PDT. Sang et al. constructed a novel GSH and near infrared (NIR) sensitive micelles to release sorafenib, SPION and NIR photosensitizer Cy7-Hex rapidly at the same time for onset of ferropotosis and lipid hydroperoxides (LPO) burst. These researches, however, still involve photosensitizers to generate ROS and GPX4 inhibitor sorafenib to induce ferropotosis.

Herein, for the first time, redox tumor microenvironment (TME)-activated metal–organic framework were constructed with Fe & Cu dual ions bridged by disulfide bonds with PEGylation (FCSP MOFs). These FCSP MOFs can be accumulated in the tumor site by the typical enhanced permeability and retention (EPR) effect, where GSH depletion and the release of Fe & Cu ions occurred due to the breakage of disulfide linkers under the GSH overexpressed TME. With the assistance of GSH depletion, more toxic ROS generated by the self-activated Fenton or Fenton-like reaction between the large amount of the released Fe & Cu ions and the endogenous H2O2 could take effect to achieve ferropotosis based chemodynamic therapy. Moreover, the depletion of GSH resulted in the highly efficient GPX4 inactivation in tumor cells. What's more, the appeared adorable photothermal effect of FCSP could be used not only for mild photothermal therapy, but also to further accelerate the Fenton reaction and enhance the therapeutic effect. To achieve better tumor therapeutic efficiency, doxorubicin (DOX), a common chemotherapeutics, was loaded into the structure, which could not only induce chemotherapy, but also generate H2O2 to further amplify the ferropotosis based chemodynamic therapy efficacy. Taking the synergy of GSH-depletion assistant GPX4 inactivation and iron-dependent Fenton reaction induced ferropotosis, mild hyperthermia, and chemotheray, excellent anti-tumor efficiency was achieved both in vitro and in vivo with minimized damage to normal tissues.

2. Materials and methods

2.1. Materials and reagents

Iron (II) chloride tetrahydrate (FeCl2\cdot4H2O), dimethyl sulfoxide (DMSO), pyridine and triethanolamine (TEA) were purchased from Macklin, Shanghai, China. Cupric chloride dihydrate (CuCl2\cdot2H2O) was purchased from Aladdin, Shanghai, China. Dithiodiglycolic acid was produced by Xiya reagent, Shandong, China. N,N-dimethylformamide (DMF) was obtained from Chemical Reagent Factory, Guangzhou, China. Polyvinylpyrrolidone (PVP, MW = 40,000) was from solarbio.com. Dulbecco’s modified Eagle’s medium (DMEM) was purchased from Gibco, Thermo Fisher, America. Other materials and reagents were purchased from Sigma—Aldrich, USA.

2.2. Preparation of Fe–Cu–SS (FCS) MOFs

A mixture of FeCl2\cdot4H2O solution, CuCl2\cdot2H2O solution (the total amount of Fe\(^{2+}\) and Cu\(^{2+}\) was 42.5 µmol in DMF), PVP (300 mg), diethyldiglycolic acid (52 µL, 100 mg/mL in DMF), and different amount of triethylamine (TEA) was dispersed in a graduated cylinder. DMF/ethanol solution was then added until the volume reached up to 13 mL (V_{DMF}/V_{ethanol} = 5/3). The solution was then transferred to a 50 mL Teflon-lined stainless autoclave after dispersed ultrasonically and reacted at 150 °C for 12 h. The final obtained FCS products were resuspended in ddH2O after being washed and centrifuged with ethanol or water until the supernatant was clear.

2.3. Drug loading and surface modification of FCS MOFs

Firstly, Fe–Cu–SS@DOX (FCS@DOX) were prepared by adding DOX (5 mg/mL, 200 µL) into the 10 mL FCS dispersion (0.5 mg/mL in ddH2O), then the obtained solution was stirred overnight under light-sealed conditions. The C18PMH–mPEG was prepared as the previous method. 5 mL C18PMH–mPEG polymer (3 mg/mL in chloroform) was sonicated for 30 min in a round-bottom flask. Then, thin film of C18PMH–mPEG was acquired by vacuum rotary evaporation. Subsequently, FCS@DOX dispersion was dumped into the round-bottom flask. After ultrasonic processing for 30 min, the FCS@DOX with surface modification were purified through removing the residual reactants by centrifugation. In order to calculate the loading capacity (Q) of DOX, the residual DOX content (R_{DOX}, µg) of the collected supernatant was calculated by UV–Vis absorption at 480 nm. The DOX loading capacity (Q) was then calculated as Q (%) = (1000–R_{DOX})/(6000–R_{DOX}) × 100.

2.4. Characterization

A JEOL JEM-2100 F TEM was applied for transmission electron microscopy (TEM) and High-angle annular dark-field scanning TEM (HAADF-STEM) based elemental mapping at an acceleration voltage of 200 kV. The size distribution of the MOFs was carried out by using a Malvern Zetasizer Nano ZS instrument (Malvern Instruments, Malvern, UK). An UV-2600 UV–Vis spectrophotometer from Shimadzu was applied to note the UV–Vis absorption spectra. An absorption analyzer Quantachrome instruments (Florida, USA) was used to performed N2 adsorption/desorption isotherms (BET). X-ray diffraction (XRD) was detected by a Thermo Fisher ARL EQUINOX 3000 X-ray diffractometer. Fourier transform infrared spectroscopy (FTIR) was applied by a Thermo Fisher Nicolet 6700.

2.5. Photothermal performance of FCS MOFs

To determine the photothermal effect, 200 µL FCS MOFs with different concentrations were exposed to an 808 nm laser (Shanghai Xilong Optoelectronics Technology Co., Ltd., China) for 5 min at different laser powers density. An infrared thermal imaging system (FLIR E50, USA) was used to note the temperature changes of the solutions. Finally, photothermal stability of FCS MOFs was determined by irradiating FCS MOFs PBS solution for five lasers on/off cycles. Ultimately, the influence of 10 mmol/L GSH to the photothermal property of FCS MOFs was purchased from Gibco, Thermo Fisher, America. Other materials and reagents were purchased from Sigma—Aldrich, USA.
explored by irradiating 200 μL 62.5 μg/mL FCSP at different laser power density before and after incubation with 10 mmol/L GSH.

2.6. In vitro TME-activated experiment

For exploring GSH-triggered cleavage of the FCSP MOFs structure, FCSP MOFs solutions were incubated in PBS with or without 10 mmol/L GSH. At predetermined time intervals, the structures were observed by TEM (JEOL). For exploring the GSH depletion capability of FCSP MOFs, FCSP MOFs solutions were incubated with 10 mmol/L GSH. At predetermined time intervals, 10 μL supernatant was taken out for analysis of GSH and oxidized glutathione (GSSG) amount by Liquid chromatography-mass spectrometry (ThermoFisher Scientific, Prelude SPLC + TSQ LC–MS/MS, USA).

The Rhodamine B (RhB) were applied to test the ·OH generation ability of FCSP MOFs because RhB could be transformed into colorless substance after being degraded by ·OH. The change at 553 nm absorbance was recorded to measure the RhB degradation. The potential influence from FCSP MOFs on the absorbance was avoided by centrifugation before measurement and the absorbance was normalized to the control.

Considering DOX would be released along with the breakage of MOFs structure, drug release kinetics of FCSP@DOX with varying condition were then researched. 1 mL FCSP@DOX (DOX concentration: 0.5 mg/mL) in a dialysis bag (MWCO 14800) was on dialysis in 100 mL PBS under light-sealed conditions at room temperature with or without 10 mmol/L GSH at pH = 7.4 or 5.8. At predetermined time intervals, the medium (1 mL) was taken out for analysis by UV–Vis spectrometer at 480 nm (Shimadzu), meanwhile the same volume of fresh PBS solutions were supplemented.

2.7. In vitro cellular experiment

Cytotoxicity of the materials was evaluated using the methyl thiazolyl tetrazolium (MTT) assay in 4T1 and MC3T3-E1 cells. Typically, under a humidified atmosphere with 1% O2, 5% CO2, 94% N2 at 37 °C, 4T1 and MC3T3-E1 cells were seeded in a 96-well culture plates at a density of 1 × 104 cells per well. After the cells were attached to the plates, various concentrations of FCSP MOFs in 100 μL culture media were used to replace the previous medium. With another 24 h incubation, the mixture of 10 μL MTT (5 mg/mL in PBS) and 100 μL culture media were added to replace the previous culture media, and the cells were incubated for another 4 h. After replacing the media with 150 μL DMSO per well, a BioTek microplate reader (BioTek, USA) was used to examine the cellular uptake experiments of FCSP@DOX.

Firstly, to confirm the intracellular GSH-induced DOX release of FCSP@DOX in high level GSH cancer cells, two cell lines, including a cancer cell (4T1) with higher GSH concentration and a normal cell line (MC3T3-E1) with lower GSH were chosen. DetaiIy, 4T1 cells and MC3T3-E1 cells were seeded in 6-well plates (2 × 105 cells per well). After being cultured for 24 h, 2 mL fresh medium containing FCSP@DOX was used to replace the medium. After 12 h, the fluorescence intensity of cells was detected by fluorescent microscope and flow cytometry analysis. Next, the influence of NIR against the cellular uptake was further explored. 4T1 cells were seeded in 6-well plates (2 × 105 cells per well). After being cultured for 24 h, 2 mL fresh medium containing FCSP@DOX and FCSP@DOX + NIR was used to replace the medium. After 4 h, 808 nm laser was applied to the cells of the irradiation groups (NIR, 0.7 W/cm2) for 5 min. After incubation for another 2 h, the fluorescence intensity of cells was evaluated by fluorescent microscope and a flow cytometer. To measure the cancer cells treatment efficiency in vitro, 4T1 cells were seeded into 96-well culture plates at a density of 1 × 105 cells per well. Then, the following treatments were exposed to the cells: control, NIR, FCSP, FCSP + NIR, FCSP + 10 mmol/L GSH, FCSP + 10 mmol/L GSH + NIR, FCSP@DOX, FCSP@DOX + NIR, FCSP@DOX + 10 mmol/L GSH, FCSP@DOX + 10 mmol/L GSH + NIR. After incubation for 4 h, 808 nm laser was applied to the cells for 5 min (0.7 W/cm2) in the laser irradiation groups (NIR). After incubation for another 24 h, the viability of cells was then measured via the MTT assay.

2.8. In vivo cancer treatment

Thirty-six female 4–6 weeks old BALB/c mice were purchased from Southern Medical University Laboratory Animal Center (Guangzhou, China). All animal experiments procedures were performed in accordance with the regulations of Animal Ethics Committee based on Southern Medical University Animal Studies Committee. 5 × 106 4T1 cells in PBS were subcutaneously injected on the right rear leg to initiate the tumors. These mice were randomly divided into six groups (n = 6, each group) when the volume of tumors reached 50 mm³: control, FCSP, FCSP + NIR, FCSP@DOX, FCSP@DOX + NIR, and free DOX.
24 h post-injection of different medicaments, the NIR treatment groups were irradiated by 808 nm for 10 min (0.7 W/cm²) with the observation of an IR thermal camera. A digital caliper was used to monitor the length and width of the tumors. Then the anti-tumor effectiveness was assessed by calculating the tumor volumes ($V = \text{Length} \times \text{Width}^2/2$. $V/V_0 \times 100\%$ was defined as relative tumor volume, where $V_0$ was the initial tumor volume before treatment. Body weights were also monitored every 2 days post-treatment. After treatment, tumor tissues of each group were stained with hematoxylin and eosin (H&E) and TUNEL to observe tumor morphology and apoptosis. In order to affirm the biosafety of FCSP MOFs, the main tissue pathological staining from PBS and FCSP@DOX + NIR group were obtained on the third day after the treatment. As for validating the mechanism of FCSP MOFs, the GPX4 level of tumor in every group was measured by Western blot.

2.9. In vitro and in vivo magnetic resonance (MR) and photoacoustic (PA) imaging

For in vitro MR/PA imaging, MOFs were dissolved with 1% agar solution to create different concentrations FCSP. Samples were transferred into 1.5 mL Eppendorf tubes and allowed to set when the mixture was fully dissolved. A Bruker Biospin MRI GmbH scanner (PharmaScan70/16 US, WI, USA) with scanning sequence for fast field echo FFE (TR = 2500, TE = 35, slice thickness = 1.0 mm), were used to obtain MR image. The photoacoustic imaging system (VEVO 2100, FUJIFILM VisualSonics, USA) were employed to gain photoacoustic imaging of various MOFs concentrations. In vivo MR/PA images of 4T1 tumor-bearing mice were obtained before and after intratumoral injection of FCSP solutions.

3. Results and discussion

3.1. Synthesis and characterization of FCSP@DOX MOFs

The TME self-activated biodegradable MOFs (FCSP@DOX) for synergetic ferroptosis based chemodynamic/photothermal/chemo therapy is schematically described in Scheme 1. Hydrothermal method was employed to synthesize MOFs with Fe & Cu dual ions bridged by disulfide bonds. According to the transmission electron microscopy (TEM) images, FCSP MOFs showed flower-like structures and a homogeneous size distribution of 127.53 ± 24.47 nm (Fig. 1A). High-angle annular dark-field scanning TEM (HAADF-STEM)-based elemental mapping revealed that the as-prepared FCSP MOFs contained Fe, Cu and S elements (Fig. 1A). X-ray diffraction patterns (XRD) were used to demonstrate the structure of the as-prepared FCSP MOFs. The results showed that the diffraction pattern matched with CuFe$_2$S$_3$, without any other representative phases detected (Supporting Information Fig. S1). The formation of the FCS MOFs structures could be influenced by the Fe/Cu ratio and TEA concentration. As shown in Supporting Information Fig. S2, the average size of FCS MOFs varied along with different proportion of Fe and Cu, and had a general trend of increasing with the increase of Fe. The flower-like MOFs structures could be obtained when the Fe/Cu value was larger than 1. With the constant Fe/Cu ratio, the average size of FCS MOFs would decrease from 200 nm to 50 nm along with increasing TEA amount (Supporting Information Fig. S3). Thus, the average size of these MOFs can be simply tuned by varying the ratio of Fe/Cu or the TEA amount. Subsequently, MOFs with average diameter about 100 nm were chosen for subsequent experiments because of its good morphology and structure. N$_2$ adsorption/desorption isotherm curves (BET) analysis indicated that FCS MOFs had a pore volume of 0.287 cm$^3$/g, a surface area of 71.05 m$^2$/g, and adsorption average pore width of 8.36 nm, respectively (Fig. 1B), suggesting their great potential to be applied for drug loading and delivery. DOX, a typical chemotherapy drug, was therefore loaded into the pores of FCS MOFs through hydrophobic interaction (FCS@DOX). Afterwards, C18PMH-mPEG was therefore be applied to modify the surface of the FCS MOFs and FCS@DOX MOFs (named as FCSP and FCSP@DOX), as it has been reported that properly modification with amphiphilic surfactant might endow the as-prepared MOFs with good water solubility and biocompatibility, avoiding rapid removal by the body’s immune system, leading to high tumor intake through the enhanced permeability and retention (EPR). To verify the successful surface modification of PEG on FCS MOFs, the Fourier transform infrared (FTIR) spectra of the FCS, C18PMH-mPEG and FCSP were obtained. As showed in Supporting Information Fig. S4, the FCSP MOFs owned both the characteristic peaks of FCS MOFs and C18PMH-MPEG, which illustrated the successful modification of C18PMH-mPEG. After being modified with C18PMH-mPEG, FCSP showed greater dispersibility and suspensibility than FCS after PEGylation as could be seen from the appearance changes after storage in PBS along with time (Supporting Information Fig. S5). The UV–Vis spectra demonstrated that FCSP@DOX exhibited an absorption peak at 480 nm (Fig. 1C), the same as the characteristic absorption peaks of DOX, confirming the successful loading of DOX into the MOFs. The drug loading capacity of DOX were calculated as 8.92%. In addition, the FCSP@DOX MOFs also displayed strong absorbance in the NIR window (Fig. 1C), denoting that they may have promising photothermal performance. To evaluate the photothermal ability of the as-prepared MOFs, the temperature changes versus different concentrations FCSP@DOX aqueous dispersions were recorded under 808 nm laser irradiation within 5 min. Remarkable photothermal stability of the FCSP MOFs was demonstrated within at least five laser on–off cycles.

![Scheme 1](image-url)  
**Scheme 1** Schematic illustration of the synthesis of TME self-activated FCSP@DOX MOFs for ferroptosis based cancer chemodynamic/photothermal/chemo therapy.
The temperature of the FCSP@DOX MOFs aqueous dispersions presented concentration and power density dependent temperature increases under 808 nm laser irradiation as shown in Fig. 1E and F, and Supporting Information Fig. S6.

3.2. In vitro TME-activated GSH depletion and fenton reaction

Considering the existence of GSH-sensitive disulfide bonds in the MOFs, it could be presumed that a redox TME-triggered GSH depletion and cleavage of the MOFs structure might happen. To verify this, the as-prepared MOFs were incubated in PBS with or without 10 mmol/L GSH to proof the redox TME responsiveness. As expected, a time-dependent MOFs decomposition could also be observed in PBS with 10 mmol/L GSH while no obvious morphology change could be observed without GSH as shown in the TEM pictures (Fig. 2A and Supporting Information Fig. S7). At the same time, it could be discovered by the liquid chromatography-mass spectrometry (LC-MS) results that GSH depletion was activated spontaneously as GSH was gradually transformed into oxidized glutathione (GSSG) along with times (Fig. 2B). These results indicated that the as-prepared MOFs could activate the depletion of GSH together with the decomposition of the mesoporous structure, leading to the release of dual ions and drugs.

As the TME-activated MOFs degradation happened, Fe and Cu dual ions would be simultaneously released for the production of toxic ·OH via Fenton or Fenton-like reaction. The ability of the Fe & Cu dual ions to generate ·OH was then investigated by the rhodamine B (RhB) decolorization experiment because the red color RhB could be degraded into colorless by ·OH. Apparent RhB degradation in Fe$^{2+}$/Cu$^{2+}$ group could be observed (~4.9%) suggesting that Fe & Cu ions could indeed react with H$_2$O$_2$ to generate ·OH via Fenton and Fenton-like reaction (Fig. 2C and D). After the addition of GSH, the ·OH generation was largely suppressed (~85.1%), indicating that generated ·OH was captured by the antioxidant GSH. FCSP MOFs, on the other hand, could only generate a little amount of ·OH due to the reaction of the surface ions without the existence of GSH (~75.2%). Activated by the GSH-rich environment, FCSP MOFs showed much more ·OH generation (~43.8%) since the GSH-induced release of Fe & Cu ions exposure to H$_2$O$_2$ and the depletion of GSH. These results demonstrated that the MOFs could exhibit specific redox-TME activated generation of toxic ·OH for ferroptosis-based cancer chemodynamic therapy. Moreover, to investigate whether external stimuli could accelerate the Fenton reaction for more ·OH generation, the temperature of the solutions was firstly increased to 46 °C. The absorbance of RhB exhibited further decrease for either H$_2$O$_2$+FCSP (~75.2%) or H$_2$O$_2$+FCSP + GSH (~43.8%) (Fig. 2E and F), illustrating that hyperthermia can efficiently promote Fenton reaction for more ·OH generation. Then, the addition of Cu$^{2+}$ into H$_2$O$_2$+FCSP or H$_2$O$_2$+FCSP + GSH groups further facilitated the decolorization of RhB to ~59.0% and ~29.1%, respectively (Fig. 2E and F), which demonstrated that the addition of Cu$^{2+}$ could lead to more ·OH generation, and the fabrication of Fe & Cu dual ions into FCS MOFs was conducive to achieve better ferroptosis effect.

Noticeably, it could also be seen that only very slight changes could be observed in photothermal performance of the MOFs after being incubated with 10 mmol/L GSH (Supporting Information Fig. 1D). The temperature of the FCSP@DOX MOFs aqueous dispersions presented concentration and power density dependent temperature increases under 808 nm laser irradiation as shown in Fig. 1E and F, and Supporting Information Fig. S6.
Fig. S8), demonstrating that the photothermal property of FCSP MOFs would not be influenced by the GSH-induced degradation of the MOFs. These results suggest that the NIR-induced hyperthermia could always be achieved as long as the MOFs were accumulated in the tumor site, whether the degradation of MOFs happened or not. Therefore, the NIR-induced hyperthermia could also be applied to accelerate Fenton reaction for more $\cdot$OH generation, enhancing the ferroptosis based cancer chemodynamic therapy.

Simultaneously with the GSH-triggered breakage of the MOFs and enhanced ferroptosis based chemodynamic therapy, the loaded DOX might also be gradually released, fulfilling the redox-activated drug release. In vitro drug release of FCSP@DOX under various conditions was then carried out. The release efficiency of FCSP@DOX MOFs was evaluated under PBS with or without 10 mmol/L GSH (pH 7.4 and pH 5.8). As expected, drug release was dramatically increased in the presence of GSH, due to the disassembly of the MOFs structures (Fig. 2G and H). The release...
amount of DOX under the condition of 10 mmol/L GSH solution reached more than 85% whether at pH 5.8 or pH 7.4 after 72 h, which was much higher than that without GSH (70% or 57%). In addition, the release of DOX at acid condition (pH 5.8) was also slightly higher than that at neutral condition (pH 7.4), suggesting a pH-responsive drug release ability, which might be resulted from the decrease of the electrostatic interaction between FCSP@DOX and DOX under the acid environments, similar to that in other nano-delivery platforms. Taking into account of the redox and acid tumor microenvironments, the GSH/pH dual-responsive DOX release property of FCSP@DOX MOFs was preferred for achieving specific tumor site release, therefore enhancing the therapeutic efficiency.

3.3. In vitro cellular experiments of redox TME self-activated ferroptosis based chemodynamic/photothermal/chemo therapy

As it is well-known, biocompatibility is the basic factor prior to bio-application. In our experiment, MTT assay was firstly implemented to assess the cytotoxicity of the as-prepared FCSP MOFs in murine normal cells MC3T3-E1 and murine breast cancer cells 4T1. No significant inhibition of the cell viability could be found at the experimental concentration for MC3T3-E1 cells, while much greater cytotoxicity against 4T1 cancer cells was observed (Fig. 3A), indicating that the FCSP MOFs possessed well biocompatibility to normal cells and showed specific toxicity to the cancer cells. Cell apoptosis was then assessed and the results showed that the proportion of apoptosis was less than 20% even in the highest concentration FCSP MOFs group, which demonstrated that apoptosis was not the main reason causing cell death (Supporting Information Fig. S9). As it is known to all, GSH level in solid tumor cells is higher than that in normal cells. Since the ability of FCSP in consuming GSH had been verified above, the cytotoxicity to 4T1 cells might be caused by the GPX4 inactivation-induced ferroptosis, as GSH depletion could inactivate GPX4 and prevent the reduction of lipid hydroperoxides. The GPX4 expression level of 4T1 cells was then determined by Western blot. As expected, the GPX4 protein expression level decreased along with the increased concentration of FCSP (Fig. 3B), showing that FCSP can down-regulate GPX4 expression through depleting its cofactor GSH. As it was designed, the as-prepared MOFs could induce ferroptosis therapy by simultaneously GPX4 inhibition and iron delivery for ROS generation via Fenton reaction. The generation of ROS was then assessed by using an ROS probe DCFH-DA. As shown in Fig. 3C, the green fluorescence from DCF become brighter and brighter along with increasing FCSP concentrations, demonstrating the generation of ROS under the tumor microenvironment. The level of ROS was further quantified by flow cytometry analysis and was consistent with the fluorescence images (Fig. 3D and E). As it has been concluded, the accumulation of lipid peroxidation is the hallmark of ferroptosis. Herein, lipid peroxidation induced by FCSP MOFs in 4T1 cells was assessed (Fig. 3F and G). As it could be noted, the green fluorescence of oxidized lipid became more and more evident along with increasing FCSP concentrations while the red fluorescence of reduced lipid had no significant change, demonstrating that the level of lipid peroxidation had increased with increasing FCSP concentrations. The results of flow cytometry analysis further verified that FCSP could increase lipid peroxidation. In general, the FCSP MOFs possess the potential to be used as ferroptosis inducer.

As it has been reported, the intracellular high level GSH in cancer cells would promote the intracellular release of drug after endocytosis in GSH-responsive drug-loaded nanoparticles.
Considering the GSH-responsive DOX release property of FCSP@DOX MOFs has been well confirmed above (Fig. 2G and H), two cell lines, including a cancer cell (4T1) with higher GSH concentration and a normal cell line (MC3T3-E1) with lower GSH were chosen to confirm the intracellular GSH-induced DOX release of FCSP@DOX in high level GSH cancer cells. The results in the Supporting Information Fig. S10 show that the fluorescence intensity of 4T1 was significantly stronger than that of MC3T3-E1 cells, indicating that the DOX could not output enhanced signals with lower GSH in the normal MC3T3-E1 cells. Therefore, these stimuli-responsive FCSP@DOX MOFs might have promising potential for highly efficient intracellular drug delivery and controlled drug release in cancer therapy. Subsequently, the fluorescence images of the FCSP@DOX were taken after being incubated with 4T1 cells for 6 h to explore NIR-promoted DOX uptake. As shown in Supporting Information Fig. S11, the red fluorescence intensity in FCSP@DOX group slightly improved after NIR irradiation was applied, implying that the temperature increase caused by NIR could improve the permeability of the cellular membrane for easier DOX uptake through affecting the fluidity of the membrane, molecular movement and the stability of the membrane. The successful delivery of DOX could not only achieve cancer chemotherapy, but also generate H$_2$O$_2$ through the catalysis of the NADPH, amplifying tumor-specific H$_2$O$_2$ level. The amplified H$_2$O$_2$ was verified following a reported method by using DCFH-DA. The increasing green fluorescence in 4T1 cells indicated the generation of H$_2$O$_2$ with the accumulation of DOX (Supporting Information Fig. S12).

Afterward, the anti-tumor effect of the FCSP@DOX MOFs was identified by incubating them with 4T1 cells under different conditions. The ROS generation was firstly determined. As shown in Fig. 4A, compared with the control group and NIR only group, increasing green fluorescence in the FCSP MOFs group could be observed. After the addition of 10 mmol/L GSH, the ROS level in MOFs group was remarkably enhanced. This phenomenon can be attributed to that GSH can lead to degradation of MOFs, releasing Fe and Cu dual ions to activate Fenton or Fenton-like reaction. In addition, the green fluorescence became much brighter after NIR irradiation, proving that photothermal can promote Fenton reaction to generate more -OH, which was beneficial to strengthen the therapeutic effect of ferroptosis based chemodynamic therapy. The flow cytometric analysis (Fig. 4B and C), which were consistent to the results of fluorescence images, further verified that FCSP MOFs possessed the ability of ROS generation through Fenton reaction and the level of ROS generation could be further enhanced by GSH-induced degradation of MOFs and NIR irradiation.
The anticancer therapeutic efficacy of the FCSP@DOX MOFs under different conditions was then assessed by MTT assay (Fig. 4D). Comparing with slightly toxic 62.5 mg/mL FCSP group, FCSP in the exist of 10 mmol/L GSH possessed significant efficiency to inhibit cancer cells, illustrating that the disassembly of FCSP MOFs triggered by GSH increased Fe and Cu ions exposure to cancer cells for \( \cdot \text{OH} \) generation. In addition, the anti-tumor effect became more evident with NIR irradiation, suggesting that NIR-induced hyperthermia can not only produce photothermal therapy, but also promote Fenton reaction to generate more \( \cdot \text{OH} \) for enhancing Fenton reaction and inducing ferroptosis (the temperature was kept at around 46 \( ^\circ \text{C} \)).

On the other hand, FCSP@DOX could suppress cells growth with the cell viability about 70%, indicating that DOX had been successfully wrapped inside the MOFs and there was only limited leakage without other stimulation. The GSH-triggered cleavage could not only release metal ions for ferroptosis based chemodynamic therapy, but also fulfill chemotherapy due to the release of DOX, and therefore better therapeutic effect could be obtained. Further treatment with NIR irradiation could perform the best anti-tumor effect due to the synchronous ferroptosis-based chemodynamic/photothermal/chemo therapy. The tumors of FCSP@DOX + NIR group achieved the best growth inhibition rate of tumor. Based on these results, FCSP@DOX MOFs have shown an excellent anti-tumor ability in vivo via TME-activated ferroptosis based cancer chemodynamic/photothermal/chemo therapy.

3.4. In vivo anti-tumor activity by redox TME self-activated ferroptosis based chemodynamic/photothermal/chemo therapy

Encouraged by the excellent outcomes in vitro, in vivo TME self-activated ferroptosis based chemodynamic/photothermal/chemo therapy of the MOFs was investigated. 4T1 tumor-bearing mice were intravenously injected by different FCSP@DOX formulation and control formulations, with or without 808 nm laser irradiation. Tumor volume and relative body weights were calculated to assess the anti-tumor effect every two days (Fig. 5A and B). The tumors in FCSP group possessed mild tumor growth inhibition compared with PBS group, indicating the FCSP MOFs had the ability to induce ferroptosis for cancer therapy by GSH depletion and ROS generation. The synergistic ferroptosis based chemodynamic/chemo therapy treatment group (FCSP@DOX group) had the increased tumor suppression than mono-therapy groups (FCSP and free DOX groups), which demonstrated that synergistic ferroptosis based chemodynamic/chemotherapy can reinforce therapeutic efficiency. When the NIR (808 nm) irradiation was applied, the temperature of the tumor area in either FCSP or FCSP@DOX group could increase and kept around 46 \( ^\circ \text{C} \) (Supporting Information Fig. S13), which is much higher than PBS group and enough to accelerate Fenton reaction to generate more \( \cdot \text{OH} \) for ferroptosis based chemodynamic therapy. The involving of mild-photothermal had more significant cancer inhibition than that without NIR irradiation, due to the enhanced ferroptosis-based chemodynamic therapy. The tumors of FCSP@DOX + NIR group were evidently inhibited both in volume (Fig. 5A and Supporting Information Fig. S14) and in weight (Fig. 5C).

There were no significant differences in weight loss of the mice in each group (seen in Fig. 5B), demonstrating that the FCSP@DOX MOFs have no obvious system toxicity. After treatment, tumor tissues of each group were removed and stained with hematoxylin and eosin (H&E) and TUNEL to observe tumor morphology and apoptosis (Fig. 5D and Supporting Information Fig. S15). There

![Scheme 2](image-url)

**Scheme 2** Schematic illustration of the TME self-activated FCSP@DOX MOFs for ferroptosis based cancer chemodynamic/photothermal/chemo therapy. Ferroptosis based chemodynamic therapy would be activated by the redox tumor environment due to GSH depletion induced GPX4 inhibition and Fe/Cu ions involved Fenton reaction. More ROS could be generated by the acceleration of Fenton reaction due to the intrinsic photothermal capability of FCSP MOFs. Moreover, the released DOX could not only induce chemotherapy, but also indirectly produce \( \cdot \text{H}_2\text{O}_2 \) to further enhance the ferroptosis based cancer chemodynamic therapy.
was no apparent cell apoptosis in the PBS group and FCSP MOFs groups, while a slight cell apoptosis in the DOX group (Fig. S15) indicating that FCSP MOFs did not induce apoptosis. Cell apoptosis increased significantly in the combined groups (FCSP@DOX), indicating FCSP@DOX achieved higher drug availability and targeted delivery efficiency than free DOX. When NIR were employed, the H&E and TUNEL results showed the significantly improved therapeutic effect of tumor as it has been already well confirmed that photothermal therapy could not only induce apoptosis itself, but also lead to the deeper drug penetration by increased intratumoral blood flow through NIR-induced increasing temperature\(^5\)\(^6\)\(^7\). Furthermore, H&E staining of the major organs (heart, liver, spleen, lung, and kidney) in FCSP@DOX + NIR group indicated that there was not tissue necrosis, demonstrating that no significant adverse effects were noted for these treatments (Supporting Information Fig. S16). As for validating the mechanism of FCSP MOFs, the GPX4 level of tumor in every group was measured by Western blot. The results found that the GPX4 protein expression level decreased in all the groups containing FCSP MOF, demonstrating that FCSP MOF can down-regulate GPX4 expression by depleting its cofactor GSH to induce ferroptosis therapy while the DOX did not influence the expression of GPX4 (Fig. 5E and F).

3.5. Magnetic resonance (MR) and photoacoustic (PA) imaging properties

To our delight, FCSP@DOX also showed good magnetic resonance (MR) and photoacoustic (PA) Imaging capabilities. In details, FCSP@DOX samples showed a concentration-dependent signal changing with a linear correlation between concentration and the T2 relaxivity value under T2-weighted \textit{in vitro} MR imaging (Supporting Information Fig. S17A). Then, FCSP@DOX was intratumorally injected into 4T1 tumors in BALB/c mice. As shown in Figs. S17C and S17D, the MR imaging signals achieved a four-fold change after/before injection in the tumor area under T2-weighted \textit{in vivo} MR imaging. PA imaging property of FCSP@DOX MOFs was also assessed \textit{in vitro} and \textit{in vivo}. According to Fig. S17B, FCSP@DOX showed a concentration-dependent rise of PA signal. There was a linear correlation between concentration and PA value. Moreover, the PA signals increased significantly in the tumor area after intratumoral injection of FCSP@DOX (Figs. S17E and S17F). These results indicated that the FCSP@DOX showed great potential to be MR and PA imaging agents.

4. Conclusions

In conclusion, for the first time, tumor microenvironment activated FCSP@DOX MOFs were constructed for ferroptosis-based cancer chemodynamic/photothermal/chemo therapy. The as-prepared FCSP@DOX MOFs could be accumulated in the tumor site through EPR effect, and disintegrated in overexpressed GSH tumor microenvironment because of GSH-induced breakage of disulfide bonds, therefore inducing ferroptosis by inhibition of GPX4 expression. Meanwhile, disintegration of FCSP@DOX MOFs leaded to gradually release of Fe, Cu ions and DOX. The release Fe & Cu dual ions could catalyze overexpressed H\(_2\)O\(_2\) to toxic \(*\text{OH}\) via Fenton or Fenton-like reaction. The inhibition of GPX4 and Fenton or Fenton-like reaction generated ROS together contributed to abundant lipid peroxidation, fulfilling ferroptosis based chemodynamic therapy. Furthermore, the intrinsic photothermal property could accelerate Fenton reaction for more \(*\text{OH}\) generation. Moreover, the co-delivered DOX could not only achieve chemotherapy by blocking topoisomerase II, but also

Figure 5 (A) The relative tumor growth curves (date are presented as mean ± SD (\(n = 5\)), *\(P < 0.05\), **\(P < 0.01\), ***\(P < 0.001\)) and (B) mice body weights change during the different treatments during the 18 days study period. (C) Tumor weight from sacrificed animals at the end of the experiment. Date are presented as mean ± SD (\(n = 5\)), *\(P < 0.05\), **\(P < 0.01\), ***\(P < 0.001\). (D) H&E stained images of tumors tissues after different treatments (scale bar = 200 \(\mu\)m). (E) Western blot results of GPX4 expression level in 4T1 tumor tissue after different treatments, and (F) their relative quantification (\(n = 3\)).
generate H$_2$O$_2$ which may further amplify the therapeutic efficacy. This system could be specifically activated by the redox tumor microenvironment achieving excellent anti-tumor effect both in vitro and in vivo by taking the synergy of GSH-depletion assistant GPX4 inactivation and iron-dependent Fenton reaction induced ferroptosis, mild hyperthermia, and chemotherapy. Overall, the inherent TME-activated MOFs for non-apoptotic ferroptosis therapy would be significant for their potential clinical translation to assist or solve the problems of tumor apoptosis.

Acknowledgments

This work was supported by the National Natural Science Foundation of China (Grant Nos. 81371559, 81671709, 81601550, 81871371, 81701711, and 82072056), Guangzhou Municipal Science and Technology Project (No. 201804010106, China), National College Students Innovation and Entrepreneurship Training Program (No. 201812121007, China). The authors would like to thank Central Laboratory, Southern Medical University, China, for MR imaging experiments, Guangzhou Institute of Energy Conversion Chinese Academy of Sciences, China, for TEM, HRTEM, and BET characterization, eceshi (www.eceshi.cn) for XRD and FTIR.

Author contributions

Bingxia Zhao and Yingjia Li as corresponding authors were responsible for experiment design, data collecting, data processing, paper writing, paper submitting and revision. Yu Liang, Li Zhang and Chao Peng as first authors were responsible for data collecting, data analysis, cell culture and animal experiment. Shiyu Zhang and Siwen Chen assisted the synthesis of MOFs. Xin Qian, Wanxian Luo assisted the synthesis of MOFs. Xin Zhang and Chao Peng as first authors were responsible for data ing, paper writing, paper submitting and revision. Yu Liang, Li responsible for experiment design, data collecting, data process- Bingxia Zhao and Yingjia Li as corresponding authors were responsible for experiment design, data collecting, data processing, paper writing, paper submitting and revision. Yu Liang, Li Zhang and Chao Peng as first authors were responsible for data collecting, data analysis, cell culture and animal experiment. Shiyu Zhang and Siwen Chen assisted the synthesis of MOFs. Xin Qian, Wanxian Luo assisted the in vivo therapeutic evaluations. Qing Dan and Yongyan Ren were in charge of imaging property of MOFs.

Conflicts of interest

The authors have no conflicts of interest to declare.

Appendix A. Supporting information

Supporting data to this article can be found online at https://doi.org/10.1016/j.apsb.2021.01.016.

References

1. Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: an iron-dependent form of non-apoptotic cell death. Cell 2012;149:1060–72.
2. Angeli JP, Shah R, Pratt DA, Conrad M. Ferroptosis inhibition: mechanisms and opportunities. Trends Pharmacol Sci 2017;38:489–98.
3. Doll S, Proneth B, Tyarina YY, Panzilius E, Kobayashi S, Ingold I, et al. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat Chem Biol 2017;13:91–8.
4. Shimada K, Skouta R, Kaplan A, Yang WS, Hayano M, Dixon SJ, et al. Global survey of cell death mechanisms reveals metabolic regulation of ferroptosis. Nat Chem Biol 2016;12:497–503.
5. Shimada K, Hayano M, Pagano NC, Stockwell BR. Cell-line selectivity improves the predictive power of pharmacogenomic analyses and helps identify NADPH as biomarker for ferroptosis sensitivity. Cell Chem Biol 2016;23:225–35.

6. Cardoso BR, Hare DJ, Bush AI, Roberts BR. Glutathione peroxidase 4: a new player in neurodegeneration?. Mol Psychiatry 2017;22:328–35.
7. Gao M, Monian P, Quadri N, Ramasamy R, Jiang X. Glutaminolysis and transferrin regulate ferroptosis. Mol Cell 2015;59:298–308.
8. Hou W, Xie Y, Song X, Sun X, Lotze MT, Zeh HJ, et al. Autophagy promotes ferroptosis by degradation of ferritin. Autophagy 2016;12:1425–8.
9. Yang WS, SriRamaratnam R, Welsch ME, Shimada K, Skouta R, Viswanathan VS, et al. Regulation of ferroptotic cancer cell death by GPX4. Cell 2014;156:317–31.
10. Stockwell BR, Friedmann Angeli JP, Bayhir Y, Bush AI, Conrad M, Dixon SJ, et al. Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell 2017;171:273–85.
11. Sengupta A, Lichten UF, Carlson BA, CatTaison C, Ryscavage AO, Mikulec C, et al. Targeted disruption of glutathione peroxidase 4 in mouse skin epithelial cells impairs postnatal hair follicle morphogenesis that is partially rescued through inhibition of COX-2. J Invest Dermatol 2013;133:1731–41.
12. Ueta T, Inoue T, Furukawa T, Tamaki Y, Nakagawa Y, Imai H, et al. Glutathione peroxidase 4 is required for maturation of photoreceptor cells. J Biol Chem 2012;287:7675–82.
13. Jiang L, Kon N, Li T, Wang SJ, Su T, Hishhooosh H, et al. Ferroptosis as a p53-mediated activity during tumour suppression. Nature 2015;520:56–62.
14. Louandre C, Marcq I, Boulihal E, Lachair E, Egdin C, Saidak Z, et al. The retinoblastoma (Rb) protein regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma cells. Cancer Lett 2015;356:971–7.
15. Sun X, Niu X, Chen R, He W, Chen D, Kang R, et al. Metallothionein-1G facilitates sorafenib resistance through inhibition of ferroptosis. Hepatology 2016;64:488–500.
16. Sehm T, Fan Z, Ghoochani A, Rauh M, Engelhorn T, Minakaki G, et al. Sulfasalazine impacts on ferroptotic cell death and alters the tumor microenvironment and glioma-induced brain edema. Onco-target 2016;7:36021–33.
17. Ooko E, Saeed MEM, Kadioglu O, Sarvi S, Colak M, Elmasaoudi A, et al. Artemisinin derivatives induce iron-dependent cell death (ferroptosis) in tumor cells. Phytomedicine 2015;22:1045–54.
18. Eling N, Reuter L, Hazin J, Hamacher-Brady A, Brady NR. Identification of artesunate as a specific activator of ferroptosis in pancreatic cancer cells. Oncoscience 2015;2:517–32.
19. Scott J, Dixon BRS. The hallmarks of ferroptosis. Annu Rev Cell Biol 2019;3:35–54.
20. Wang S, Liao H, Li F, Ding L. A mini-review and perspective on ferroptosis-inducing strategies in cancer therapy. Chin Chem Lett 2019;30:847–52.
21. Shen Z, Song J, Yang BC, Zhou Z, Wu A, Chen X. Emerging strategies of cancer therapy based on ferroptosis. Adv Mater 2018;30:1704007.
22. Meng X, Deng J, Liu F, Guo T, Liu M, Dai P, et al. Triggered all-active metal organic framework: ferroptosis machinery contributes to the apoptotic photodynamic antitumor therapy. Nano Lett 2019;19:7866–76.
23. Shan X, Li S, Sun B, Chen Q, Sun J, He Z, et al. Ferroptosis-driven nanotherapeutics for cancer treatment. J Control Release 2020;319:322–32.
24. Szatrowski TP, Nathan CF. Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res 1991;51:794–8.
25. Dan Q, Hu D, Ge Y, Zhang S, Li S, Gao D, et al. Ultrasmall thera-stic nanoparticles to modulate tumor hypoxia for augmenting photodynamic therapy and radiotherapy. Biomater Sci 2020;8:973–87.
26. Huo M, Wang L, Chen Y, Shi J. Tumor-selective catalytic nanomedicine by nanocatalyst delivery. Nat Commun 2017;8:357.
27. An Q, Sun C, Li D, Xu K, Guo J, Wang C. Peroxidase-like activity of Fe$_3$O$_4$@carbon nanoparticles enhances ascorbic acid-induced oxidative stress and selective damage to PC-3 prostate cancer cells. ACS Appl Mater Interfaces 2013;5:13248–57.
28. Zanganeh S, Hutter G, Spitler R, Lenkov O, Mahmoudi M, Shaw A, et al. Iron oxide nanoparticles inhibit tumor growth by inducing pro-inflammatory macrophage polarization in tumor tissues. Nat Nanotechnol 2016;11:986–94.

29. Zhang C, Bu W, Ni D, Zhang S, Li Q, Yao Z, et al. Synthesis of iron nanometallic glasses and their application in cancer therapy by a localized Fenton Reaction. Angew Chem Int Ed Engl 2016;55:2101–6.

30. Bi H, Dai Y, Yang P, Xu J, Yang D, Gai S, et al. Glutathione mediated size-tunable UCNP@Pt(IV)-ZnFe2O4 nanocomposite for multiple bioimaging guided synergistic therapy. Small 2018;14:e1703809.

31. Tang Z, Liu Y, He M, Bu W. Chemodynamic therapy: tumor microenvironment-mediated Fenton and fenton-like reactions. Angew Chem Int Ed Engl 2019;58:946–56.

32. Cai W, Wang J, Chu C, Chen W, Wu C, Liu G. Metal-organic framework-based stimuli-responsive systems for drug delivery. Adv Sci (Weinh) 2019;6:1801526.

33. Zheng DW, Lei Q, Zhu YJ, Fan JX, Li CX, Li C, et al. Switching apoptosis to ferroptosis: metal-organic network for high-efficiency anticancer therapy. Nano Lett 2017;17:284–91.

34. Ranji-Burachaloo H, Karimi F, Xie K, Fu Q, Gurr PA, Dunstan DE, et al. Mitochondrial membrane anchored photosensitive nano-device for lipid hydroperoxides burst and inducing ferroptosis to surmount therapy-resistant cancer. Theranostics 2019;9:6209–23.

35. Wang S, Yang L, Cho HY, Dean CST, Zhang H, Zhang Q, et al. Programmed degradation of a hierarchical nanoparticle with redox and light responsivity for self-activated photo-chemical enhanced chemo-dynamic therapy. Biomaterials 2019;224:119498.

36. Torchi A, Simonelli F, Ferrando R, Rossi G. Local enhancement of photothermal cancer ablation by means of siRNA delivery. J Control Release 2018;288:126–35.

37. Sun M, Shahzeydi A. Facile and green synthesis of copper nanostructures. ACS Appl Mater Interfaces 2014;6:9486–93.

38. Nie X, Xia L, Wang HL, Chen G, Wu B, Zeng TY, et al. Photothermal therapy nanomaterials boosting transformation of Fe(III) into Fe(II) in tumor cells for highly improving chemodynamic therapy. ACS Appl Mater Interfaces 2019;11:31735–42.

39. Sun M, Shahzeydi A. Facile and green synthesis of copper nanoparticles loaded on the amorphous carbon nitride for the oxidation of cyclohexane. Chem Eng J 2019;370:1310–21.

40. Cramer SL, Sahia A, Liu J, Tadi S, Triziani S, Yan W, et al. Systemic depletion of t-cysteine with cysteine increase reactive oxygen species and suppresses tumor growth. Nat Med 2017;23:120–7.

41. Wang S, Li F, Qiao R, Hu X, Liao H, Chen L, et al. Arginine-rich manganese silicate nanobubbles as a ferroptosis-inducing agent for tumor-targeted theranostics. ACS Nano 2018;12:12380–92.

42. Fan H, Yan G, Zhao Z, Hu X, Zhang W, Liu H, et al. A smart photosensitizer-manganese dioxide nanosystem for enhanced photodynamic therapy by reducing glutathione levels in cancer cells. Angew Chem Int Ed Engl 2016;55:5477–82.

43. Lin LS, Song J, Song L, Ke K, Liu Y, Zhou Z, et al. Simultaneous Fenton-like ion delivery and glutathione depletion by MnO2-based nanoagent to enhance chemodynamic therapy. Angew Chem Int Ed Engl 2018;57:4902–6.

44. Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, Kulp AN, et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 2009;458:780–3.

45. Ross D. Glutathione, free radicals and chemotherapeutic agents. Mechanisms of free-radical induced toxicity and glutathione-dependent protection. Pharmacol Therapeut 1987;37:231–49.

46. Arrick BA, Nathan CF. Glutathione metabolism as a determinant of therapeutic efficacy: a review. Cancer Res 1984;44:4224–32.

47. Liu T, Liu W, Zhang M, Yu W, Gao F, Li C, et al. Ferrous-supply-regeneration nanoengineering for cancer-cell-specific ferroptosis in combination with imaging-guided photodynamic therapy. ACS Nano 2018;12:12181–92.

48. Sang M, Luo R, Bai Y, Dou J, Zhang Z, Liu F, et al. Mitochondrial membrane anchored photosensitive nano-device for lipid hydroperoxides burst and inducing ferroptosis to surmount therapy-resistant cancer. Nanoscale 2019;9:6209–23.